Summit Therapeutics PLC (SMMT) Given New $29.00 Price Target at Royal Bank Of Canada
Summit Therapeutics PLC (NASDAQ:SMMT) had its price target boosted by Royal Bank Of Canada from $26.00 to $29.00 in a research note issued to investors on Wednesday. The brokerage currently has an outperform rating on the stock.
A number of other brokerages have also recently weighed in on SMMT. Canaccord Genuity set a $28.00 price target on shares of Summit Therapeutics PLC and gave the company a buy rating in a research report on Wednesday, October 5th. Oppenheimer Holdings Inc. reiterated an outperform rating and set a $28.00 price target on shares of Summit Therapeutics PLC in a research report on Wednesday, October 5th. Needham & Company LLC lifted their price target on shares of Summit Therapeutics PLC from $22.00 to $30.00 and gave the company a buy rating in a research report on Tuesday, October 4th. Zacks Investment Research cut shares of Summit Therapeutics PLC from a buy rating to a hold rating in a research report on Wednesday, November 9th. Finally, HC Wainwright initiated coverage on shares of Summit Therapeutics PLC in a research report on Friday, September 16th. They set a buy rating and a $26.00 price target for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $25.29.
Summit Therapeutics PLC (NASDAQ:SMMT) traded down 0.36% during midday trading on Wednesday, reaching $11.01. 28,890 shares of the company were exchanged. The firm has a 50-day moving average price of $0.00 and a 200-day moving average price of $0.00. Summit Therapeutics PLC has a 52 week low of $4.26 and a 52 week high of $19.75.
An institutional investor recently raised its position in Summit Therapeutics PLC stock. AXA boosted its stake in Summit Therapeutics PLC (NASDAQ:SMMT) by 1.5% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 382,705 shares of the company’s stock after buying an additional 5,500 shares during the period. AXA owned about 3.12% of Summit Therapeutics PLC worth $2,989,000 at the end of the most recent quarter. 23.43% of the stock is owned by hedge funds and other institutional investors.
Summit Therapeutics PLC Company Profile
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Stock Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related stocks with our FREE daily email newsletter.